Article and Video CATEGORIES

Cancer Journey

Search By

Is the Survival Benefit with Avastin Added to Chemotherapy Enough to Change the Standard of Care in Mesothelioma?
Author
GRACE Videos and Articles

WCLC_2015_Avastin_Chemotherapy_Mesothelioma_Survival_Benefit_Enough

 

Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.

[powerpress]

Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

Dr. West:  So, one of the other topics that’s covered in this broad thoracic malignancies conference is mesothelioma, where one of the biggest bits of news that we got this year actually came at ASCO, earlier this year, in a French trial that showed that adding Avastin (bevacizumab) to standard chemotherapy, in this case, cisplatin and Alimta (pemetrexed), seemed to improve survival in a clinically significant way. What do you think of these data — is this changing practice for you or around you, Ben?

Dr. Solomon:  Sure, look, I think it’s an important study — the initial study that showed benefit of cisplatin and pemetrexed, over cisplatin alone, was the first phase three study that showed a survival benefit in mesothelioma. This is the second study, and I think the benefits are meaningful. There was an improvement in progression-free survival of about two months — the improvement in overall survival was a bit more than that. So, I do think that that difference is meaningful, and I think it’s likely that bevacizumab, in that context, will get incorporated into standard practice.

Dr. West:  What do you say?

Dr. Horn:  I think that is possible — what I worry is that pemetrexed and bevacizumab together is a more toxic combination, and it is not as easy and as tolerable as pemetrexed alone, but for those patients who can tolerate it, it is a good, new treatment option for them.

Dr. West:  So it’s not something you’re uniformly inclined to incorporate for most or all of your patients with mesothelioma?

Dr. Horn:  It’s such a rare disease, so not right now. What I also worry about is a lot of the mesothelioma patients are older, and, so, that same worry about tolerability.

Next Previous link

Previous PostNext Post

Related Content

Article
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.
Image
Blood Cancer Video Library 2024
Video
In these videos,  Dr. Levavi discusses what blastic plasmacytoid dendritic cell neoplasm (BPDCN) is, why people get it, how frequent the disease is, who it affects and its epidemiology. Also, how patients are diagnosed, recent advances among other topics related to BPDCN.  To watch the complete playlist, click here.  

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Recent Comments

JOIN THE CONVERSATION
Thank you for sharing
By LeviDrake on
Hi bluesun,I don't know of…
By JanineT GRACE … on
Amivantamab and Lazertinib
By happybluesun on
Glad to help.  FYI, I just…
By JanineT GRACE … on